Call for proposals
Roadmaps to human biology-based disease research
To support strategic scientific dialogue around the concept of extending the vision of “21st century toxicology” to the wider biosciences, Humane Society International and The Humane Society of the United States are offering grants of up to $10,000 (USD) in funding to support the development and open-access publication of in-depth, independent review articles in discrete areas of human disease/biomedicine by health scientists with relevant expertise.
Each review should:
• Examine the state of the science in a specific area of human biomedicine, including current understanding of the underlying pathophysiological pathways and networks;
• Critically evaluate the human relevance, translational success and limitations of conventional research models;
• Offer concrete recommendations/roadmap for optimizing the funding and use of advanced, human-specific tools and approaches (pathway paradigm as an organizing framework, primary human cells/tissues, iPSC, organoids, bioengineering, computational systems biology modeling, etc.) in the disease area under discussion; and
• Be accepted for publication in a high-visibility, peer-reviewed journal.
A scientific workshop will be convened in early 2019 to explore the findings and recommendations of funded review articles. Lead authors will be invited to attend and present their work, and contribute to a subsequent workshop report. Travel, accommodations and meals will be arranged.
|Application process opens||8 May 2017|
|Deadline for online applications||30 June 2017|
|Notification of successful candidates, legal paperwork
and commencement of grant period
|17 July 2017|
|Draft review submitted to HSI-HSUS||1 November 2017|
|Final draft submitted to HSI-HSUS
First payment due upon acceptance by HSI-HSUS
|8 December 2017|
|Publication of review article
Final payment due upon acceptance for publication
|By end of 2018|
|Participation in scientific workshop organized by HSI-HSUS||Early 2019|
|Workshop report article||By end of 2019|
Who can apply
• Health researchers holding a PhD (or equivalent) degree and be able to demonstrate relevant experience in the disease area they propose to review.
• Eligible individuals may currently be employed in a health research position in the academic, private or public sectors, or may have retired from such a position.
• Applications will be accepted from single authors or groups.
• The current call is restricted to applicants in the United States, Canada, European Union and South Korea.
How to apply
The application form can be downloaded below and submitted by email. Applicants must read the legal agreement and funding conditions below before completing their application.
A brief CV of no more than two pages for each applicant is also required, and PDFs of up to four recent publications in the field of the disease that they wish to review should be included.
High visibility publication of the review is a requirement of this funding; therefore, applicants are required to identify three candidate peer-reviewed journals of suitable remit for their proposal.
Final applications should be submitted by email to Dr. Lindsay Marshall at email@example.com.
It is expected that grant funding shall be used to enable applicants to dedicate their time to the production of a high-quality review article within a relatively short (3-4 month) timeframe, and will be used to cover the open-access article publishing charge for publication in an appropriate open-access peer-reviewed scientific journal.
Successful applicants shall be paid in arrears under the following terms and conditions:
• $3,500 shall be payable upon completion of the review to the satisfaction of HSI/HSUS;
• $6,500 shall be payable upon acceptance for publication by an appropriate, open-access peer-reviewed scientific journal agreed by HSI/HSUS;
Disease areas not eligible funding under this call include Alzheimer’s and Parkinson’s disease, addiction, ALS/motor neuron disease, stroke, asthma/COPD, autism, tuberculosis, liver cholestasis and autoimmunity, as extensive reviews are already available.